Yiming Cell Completes Series C Financing of Hundreds of Millions of Yuan

Recently, Yiming Cell Biotechnology Co., Ltd. (abbreviation: Yiming Cell) completed a series C financing of several hundred million yuan. This round of financing was led by GoldStone Investment and Lyon Capital, followed by Huada Win-Win, Xing Investment Capital, etc. The old shareholders Huagai Capital, Fangfu Capital, IDG Capital, etc. continued to increase their investment. This round of financing is another milestone in Yiming Cell’s rapid and steady progress. It is the investment institution’s high recognition and strong confidence in Yiming Cell’s achievements in the field of cell and gene therapy (CGT) CDMO, as well as its future development strategy and vision.

This round of financing will further accelerate the global layout of Yiming Cell, accelerate the platform construction of CMC R&D centers in the United States and Canada, continue to promote the development and innovation of CGT carrier technologies and processes, and continuously enhance Yiming Cell’s leading position in the field of one-stop CDMO services in the CGT field , to increase the production capacity of GMP AAV, plasmid, lentivirus, adenovirus, CAR-T, iPSc and other products in an all-round way, and strongly empower the development and industrial transformation of new CGT drugs at home and abroad.

Yiming Cell is committed to CGT one-stop CDMO service, and vigorously builds domestic GMP base construction. Yiming Cell Suzhou CDMO Base has been operating steadily since it was put into production in March 2022, and has reached a number of strategic cooperation with many customers. Covering an area of ​​9000m2, the Suzhou base has more advanced process development and production workshops, dozens of GMP production lines, the scale of eukaryotic cell culture is 50L-200L-500L-2000L, and the scale of prokaryotic fermentation is 10L-50L-200L. Purification process, fully escort gene therapy companies.